Kawasaki Disease: an Update

Area of Science:

• Pediatric Rheumatology
• Immunology
• Infectious Disease Epidemiology

Background:

• Kawasaki disease (KD) is a rare, acute febrile vasculitis primarily affecting children under five.
• Its etiology remains elusive, with current theories pointing to an immune response triggered by an unknown agent in genetically predisposed individuals.
• KD diagnosis relies on clinical criteria, with atypical presentations posing diagnostic challenges and similar risks for coronary artery abnormalities.

Purpose of the Study:

• To provide current insights into the epidemiology, pathogenesis, and therapeutic advancements in Kawasaki disease.
• To review recent developments in managing complex and intravenous immunoglobulin (IVIG)-refractory KD cases.
• To discuss the emergence of multisystem inflammatory syndrome (MIS) with KD-like features, particularly its association with COVID-19.

Main Methods:

• Review of recent literature on Kawasaki disease epidemiology and pathogenesis.
• Analysis of treatment strategies, including standard care and advanced therapies for refractory cases.
• Examination of emerging inflammatory conditions with KD-like features, such as MIS-C.

Main Results:

• Intravenous immunoglobulin (IVIG) and aspirin significantly reduce coronary artery complications in KD.
• Novel immunomodulatory therapies are increasingly used for complex or IVIG-refractory KD.
• Multisystem inflammatory syndrome (MIS), potentially linked to SARS-CoV-2, shares clinical similarities with KD.

Conclusions:

• While standard treatments are effective, refractory KD necessitates advanced immunomodulatory approaches.
• Understanding the pathogenesis of KD is crucial for developing targeted therapies.
• The recognition of MIS highlights the importance of recognizing KD-like presentations and their potential triggers, including viral infections like COVID-19.